Soligenix Reports Q3 2025 Results with Key Clinical Milestones for Rare Disease Treatments
Soligenix Inc. announced positive clinical progress for its rare disease pipeline including upcoming Phase 2a psoriasis results and maintained safety profile for HyBryte™ in CTCL treatment, supported by sufficient funding through 2026.
Soligenix Inc. (NASDAQ: SNGX) reported third quarter 2025 financial results while highlighting significant clinical progress across its rare disease treatment pipeline. The late-stage biopharmaceutical company confirmed upcoming milestones including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte™ study in cutaneous T-cell lymphoma (CTCL).
Chief Executive Officer Christopher J. Schaber, PhD, announced that the first Data Monitoring Committee review for HyBryte™ found no safety concerns, maintaining a consistent safety profile across clinical trials. This development reinforces the potential of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for CTCL treatment.
The company's financial position remains stable with $10.5 million in cash as of September 30, 2025, providing an operating runway expected to extend through 2026. This financial stability supports Soligenix's evaluation of strategic options to advance its late-stage pipeline while managing development costs effectively.
Beyond the immediate clinical programs, Soligenix maintains a diversified pipeline through its two business segments. The Specialized BioTherapeutics segment includes development programs expanding synthetic hypericin (SGX302) into psoriasis treatment, along with first-in-class innate defense regulator technology dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behcet's Disease.
The Public Health Solutions business segment continues advancing vaccine candidates with government support, incorporating the company's proprietary heat stabilization platform technology ThermoVax®. This segment has received funding from multiple government agencies including the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. The full press release detailing the quarterly results and clinical updates can be accessed at https://ibn.fm/BA8C2. These developments position Soligenix to potentially address significant unmet medical needs in rare disease treatment while maintaining financial stability through strategic planning and government-supported research initiatives.